Background Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling
pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK …

Background Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma
relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or …

Background Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis.
Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed …

Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell
lymphoma (MCL) who have received one prior therapy. We report the updated safety and …

Background Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma.
Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor …

In recent years, the number of approved and investigational agents that can be safely
administered for the treatment of lymphoma patients for a prolonged period of time has …

We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton
tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell …

Despite unprecedented clinical activity in mantle cell lymphoma (MCL), primary and acquired
resistance to ibrutinib is common. The outcomes and ideal management of patients who …

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin’s lymphoma that
generally affects older individuals and continues to have one of the worst outcomes of all …

Tremendous progress in treatment and outcomes has been achieved across the whole
range of haematological malignancies in the past two decades. Although cure rates for …